Qualification of Cord Blood Units for an Autologous Infusion Program for Pediatric Patients with Acquired Brain Injuries  by Allison-Thacker, J. et al.
Poster Session I S251patients were re-started on a tyrosine kinase inhibitor (Imatinib -5,
Dasatinib -1). One patient had delayed recovery of blood counts
and was not restarted on a TKI. One patient relapsed 4 months
post PBSCT and died due to refractory disease. Remaining patients
remain alive at median 26 months (range 12-86) in complete molec-
ular remission. Of note the patient that never received post-trans-
plant TKI remains in complete molecular remission 86 months
following PBSCT.
Conclusion: Autologous stem cell transplantation in combination
with tyrosine kinase inhibition can provide long term durable remis-
sions in patients with Ph+ ALLwho are unable to undergo allogeneic
stem cell transplantation.
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COMPARISON OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANS-
PLANTATION WITH AND WITHOUT METAIODOBENZYLGUANIDINE
(MIBG) IN PATIENTS WITH HIGH RISK NEUROBLASTOMA
Hamidieh, A.A.1, Beigi, D.2, Fallahi, B.2, Behfar, M.1, Jalili, M.1,
Hamdi, A.1, Hosseini, A.1, Ghavamzadeh, A.1 1Tehran University of
Medical Sciences, Tehran, Islamic Republic of Iran; 2Tehran University
of Medical Sciences, Tehran, Islamic Republic of Iran
Background: Autologous Hematopoietic Stem Cell transplantation
(auto-HSCT) has been considered for treatment of patients with
high risk neuroblastoma. In this study we compared two main
strategies of auto-HSCT for patients with high risk neuroblastoma:
auto-HSCT alone in patient with negative diagnostic MIBG and
auto-HSCT with therapeutic MIBG before HSCT in patient with
positive diagnostic MIBG.
Methods: The results of 14 patients with high risk neuroblastoma
who underwent auto-HSCT at our center from 2008 to 2011,
were analyzed. Median age at transplantation was 4.5 years (range
5 2-7, 50% male). N-Myc amplification was positive in 9 patients
(64.3%). Diagnostic MIBG was asked at first visit from all patients
who were referred to our center for HSCT. Patients were divided
into two groups according to the result of diagnostic MIBG:
MIBG-avid (n 5 6) and non MIBG-avid (n 5 8). MIBG-avid pa-
tients received 131I-MIBG (12 mci/kg) on day 21 before transplanta-
tion. The conditioning regimen used in all patients consisted of
etoposide (1200mg/m2 total dose divided for 5 days), carboplatin
(1500mg/m2 total dose divided for 5 days), and melphalan (210mg/
m2 total dose divided for 3 days). The source of stem cells was pe-
ripheral blood in patients. The median numbers of MNC and
CD34 injected were 10.71x108/kg /kg, 1.7x106/kg, respectively. All
patients received 13-cis-retinoic acid (120-160 mg/m2 2 weeks per
month) from day +60 to one year after transplantation.
Results: Engraftment occurred in all patients. The median time to
neutrophil and platelet engraftment were 13 (10-18 days) and 17
days (13-21 days), respectively that was not significantly different
between two groups. No severe side effects (like neutropenia, throm-
bocytopenia and mucusitis) were observed in any patients in MIBG-
avid group. With a median follow-up time of 13 months (2-35
months), 2 patients (33.3%) relapsed in MIBG-avid group (both
died) and 5 patients (62.5%) relapsed in non MIBG-avid group (4
of them died).
Conclusion:Despite nonsignificant difference between two groups,
MIBG-avid patients seem to have better survival and lower relapse
rate. Therefore, much greater number of cases is needed to clarify
the role of MIBG therapy in pre-transplant conditioning regimen
for autologous hematopoietic stem cell transplantation in high risk
neuroblastoma patients.127
COMPARISON OF BUSULFAN +MELPHALAN TOMELPHALAN 200 MG/M2
AS PREPARATIVE REGIMEN FOR AUTOLOGOUS TRANSPLANTATION IN
MULTIPLE MYELOMA
Ahmed, S., Dinh, Y., Rondon, G., Andersson, B., Jones, R., Bashir, Q.,
Shah, N., Popat, U., Champlin, R.E., Qazilbash, M.H., Kebriaei, P.
The University of Texas, M.D. Anderson Cancer Center, Houston, TX
Background:High-dose chemotherapy with melphalan 200 mg/m2
(Mel 200) followed by autologous hematopoietic stem cell transplan-tation (auto-HCT) is the standard treatment for transplant-eligible
patients (pts) withmultiplemyeloma (MM).Most patients eventually
relapse after auto-HCT and in efforts to improve the efficacy of the
preparative regimen, several groups have evaluated the combination
of busulfan (Bu) and melphalan (Mel). We studied the safety and ef-
ficacy of a combination of Bu and Mel (Bu-Mel) in patients with ad-
vanced lymphoid malignancies, including MM. (Kebriaei P, et al.,
Biol Blood Marrow Transplant 2011; 17: 412-420). In this study
we compared outcomes of patients with MM who received Bu-Mel
with a control group of patients who received Mel 200 for auto-
HCT for MM.
Methods: We identified 30 patients with MM in first remission
who received Bu-Mel followed by auto-HCT between 1/2005
and 10/2010. They were compared to a control group (4:1) of
120 patients with MM who received Mel 200 as conditioning reg-
imen for auto-HCT. The groups were matched for year of auto-
HCT, age at auto-HCT (+/- 4 yrs), cytogenetic abnormalities,
and disease status at auto-HCT. The primary objective was to
study impact of conditioning regimens on complete (CR) and
overall response rate (ORR), progression-free (PFS) and overall
survival (OS).
Results: Patient characteristics and major outcomes are summa-
rized in the attached Table. Bu-Mel and Mel 200 groups were
similar in median age, renal function and chemosensitivity at auto-
HCT, and time from diagnosis to auto-HCT (Table). Median
time to neutrophil engraftment in both groups was 10 days (p 5
0.8). There was no significant difference in 100-day transplant-
related mortality (0% vs. 0.8%, p 5 0.2) or grade 2-4 non-he-
matologic toxicity between Bu-Mel and Mel 200 (80% vs. 66%, p
5 0.18) or veno-occlusive disease (none in either group). CR rates
in Bu-Mel and Mel 200 were 30% vs. 34% (p 5 0.82, Table).
Median follow up was 27.3 months. Median PFS for Bu-Mel and
Mel 200 were 24.1 and 26.2 months, respectively (p 5 0.43,
Figure 1). Median OS for Bu-Mel and Mel 200 has not yet been
reached (p 5 0.24, Figure 2).
Conclusions: In this large single center study with long follow up,
we demonstrated that a preparative regimen of Bu-Mel is compara-
ble to Mel 200 in safety and efficacy. The two regimens will be com-
pared in a prospective, randomized trial.
Table. Patient Characteristics/Outcomes
Bu-Mel (n 5 30) Mel200 (n 5 120) pMales 17 68 1.00
Median Age 52.5 52 0.19
Abn Cytogenetics 12 48 1.00
High Risk CG 2 8 1.00
Serum Creat > 1.5 at TP 1 8 0.68
Median Interval Dx to TP 6.8 mo 6.7 mo 0.44
Median CD34 4.63 4.76 0.31
Chemosensitive (>/ 5 atTP) 13% 9% 0.50
Median days to engraftment
ANC ./ 5 50010 10 0.81CR 9, 30% 41, 34% 0.82
CR + VGPR 20, 66% 72, 60% 0.53
ORR 27, 90% 110, 83% 0.57
100-day TRM 0 1, 0.8% 0.20
Grade 2-4 AE 24, 80% 79, 66% 0.18
Median PFS 24.1 mo 26.2 mo 0.43
Median OS not reached not reached 0.24128
QUALIFICATION OF CORD BLOOD UNITS FOR AN AUTOLOGOUS
INFUSION PROGRAM FOR PEDIATRIC PATIENTS WITH ACQUIRED BRAIN
INJURIES
Allison-Thacker, J., Fitzgerald, A., Sun, J., McLaughlin, C., Waters-
Pick, B., Vinesett, R., Kurtzberg, J. Duke University Medical Center,
Durham, NC
Autologous umbilical cord blood (CB) infusion for the treatment
of brain injuries in young children has been studied by the Pediatric
Blood and Marrow Transplant (PBMT) Program at Duke Univer-
sity Medical Center since 2004. The majority of infusions have
been used to treat children with Hypoxic Ischemic Encephalopathy
S252 Poster Session I(HIE), cerebral palsy (CP) or congenital hydrocephalus. Most of the
CB units (CBU) were privately banked through parental initiatives at
the time of the baby’s birth. Variable testing was performed by the
banks at the time of CB cryopreservation and storage. From 2004
to 2010, the program was approached by thousands of families seek-
ing treatment for their children. Their calls, emails and letters were
catalogued in a database and characterized.
CBUs were shipped to Duke from private cord blood banks (CBB)
for administration after prequalification of CBB records. To qualify,
the number of total nucleated cells had to deliver 1X10e7 cells/kg of
recipient body weight, have negative donor screening tests and neg-
ative sterility cultures. Patient andCB samples were testedwithHLA
low-resolution typing to confirm patient/unit match. ACB reference
sample was also shipped to Duke for potency testing including enu-
meration of colony forming units, viability and CD34 counts. Upon
confirmation of eligibility, shipment was arranged by Duke’s Stem
Cell Laboratory and the private CBB.
From March 2004 to December 2010, the PBMT program re-
ceived approximately 2,667 inquiries about CB stem cell treatment
for children with brain injuries. Of those, 745 parents had privately
banked their child’s CB. When asked to provide the CB report
from the CBB, 139 did not send a report and had no further contact
with the program. Some children (351) were ineligible: 264 due to
patient reasons including diagnosis (165), incomplete records (81),
and parents declining (10); and 91 due to CB reasons including
low cell count (57), positive sterility cultures (24), and bank issues
(10). A total of 255 children were successfully infused with their
own CB without any serious adverse events. Units were shipped
from 57 different CBBs.
In summary, 27.9% of contacts had privately stored their baby’s
CB.Of these, 34.2%were eligible for infusion.Of ineligible patients,
25.9% were due to problems with CBU quality. The infusions were
well tolerated (Sun et al, Transfusion 2010). Studies to determine ef-
ficacy in babies and children with HIE, CP and congenital hydro-
cephalus are ongoing.129
OUTPATIENT STEM CELL TRANSPLANTATION USING A REDUCED-INTEN-
SITY CONDITIONING IN TYPE 1 DIABETES MELLITUS
Cantu-Rodrıguez, O.G., Trevi~no-Montemayor, O.R., Lavalle-Gonzalez, F.,
Zapata-Garrido, A., Gutierrez-Aguirre, C.H., Gonzalez-Llano, O.,
Gomez-Almaguer, D., Villarreal-Perez, J.Z. Facultad deMedicina, Hospital
Universitario, UANL, Monterrey, Nuevo Leon, Mexico
Introduction: In recent years a theory of a possible reconstitution of
the immune system using autologous hematopoietic stem cell trans-
plantation (A-HSCT) has emerged, in this basis and because of the
pathogenesis, patients with newly diagnosis of type 1 diabetes melli-
tus (DM-1) may benefit with this therapy.
Objective: To quantify the decrease in insulin requirements in pa-
tients with DM-1 who underwent A-HSCT using reduced-intensity
conditioning (RIC).
Material and Methods: Prospective and experimental study, in
which have been included 8 patients with newly diagnosed DM-1,
confirmed by measurement of seric anti-GAD antibodies and pan-
creatic reserve measured from C-peptide levels, in whom was per-
formed A-HCT using RIC on an outpatient basis. A two-day
ciclofosfamide (CFM) scheme as well as G-CSF was used for mobi-
lization. The conditioning regimen was based on a four-day CFM
and fludarabine.
Results:Of the 8 cases, 6 patients had received the therapy, and 2 are
in process; 5 male and 3 female patients, median of age was found in
12.5 (4-18), and the median time from the diagnosis of DM-1 is 3
months (0-9). During the 2-16 months follow-up (median 12) of pa-
tients who underwent the procedure, 2 are currently free from insu-
lin use and the remaining have decreased their use by 80%, 50%,
35% and 0% respectively; the mean amount of CD34 + cells infused
is in 10.41x106 (3.78-19.3 x 106). In 5 of the 6 patients only one rec-
ollection procedure were needed, the other patient required a sec-
ond.
Conclusion: After 12 months follow-up, 5/6 patients had showed
a decrease in the insulin requirements and none patient had devel-
oped any complication or needed hospitalization.
Trial Registration.ClinicalTrials.gov Identifier: NCT01121029.130
2MELPHALAN 180mg/m CAN BE SAFELY ADMINISTERED AS CONDITION-
ING REGIMEN PRIOR TO AN AUTOLOGOUS STEM CELL TRANSPLANTA-
TION IN MULTIPLE MYELOMA PATIENTS WITH CREATININE
CLEARANCE#60ml/min/1.73 m2 WITH USE OF PALIFERMIN FOR CYTO-
PROTECTION: RESULTS OF A PHASE I TRIAL
Abidi, M.H.1,2, Agarwal, R.3, Tageja, N.4, Ayash, L.1,2,
Ventimiglia, M.2, Deol, A.1,2, Al-Kadhimi, Z.1,2, Lum, L.1,2,
Ratanatharathorn, V.1,2, Abrams, J.1,2, Uberti, J.P.1,2 1Wayne State
University, Detroit, MI; 2Karmanos Cancer Center, Detroit, MI; 3Syn-
ergy Medical Education Alliance, Central Michigan University, Saginaw,
MI; 4NIH, Bethesda, MD
The majority of multiple myeloma (MM) patients (pts) with ab-
normal renal function (AbRF) receive attenuated dose of therapy.
Melphalan (M) is the most effective conditioning for MM pts receiv-
ing autologous stem cells transplant (ASCT). M 140 mg/m2 is the
standard of care in pts with AbRF, asM 200mg/m2 resulted in severe
oral mucositis (OM). Palifermin (P) as a cytoprotective agent has
demonstrated efficacy in reducing the intensity & duration of OM.
Due to lack of prospective data on the use of P in MM pts with
AbRF, we designed this study to determine the maximum tolerated
dose (MTD) of M when used with P, in order to decrease OM.
Methods: Eligibility criteria: creatinine clearance# 60ml/min/1.73
m2, age $18 years, Durie-Salmon stage 2/3, ECOG PS # 2, no di-
alysis, no active OM & a suitable candidate for ASCT. Level (L) 1
began at M 140 mg/m2 with P 60 mcg/kg/d, given as I.V bolus on
Day -5,-4, -3 and Day +1, +2 & +3 (Stem cells infused on Day 0).
Mwas given onD-2& dose-escalation proceeded at 20mg/m2 incre-
ments, up to a maximum dose of 200 mg/m2 in L4. If no symptom-
atic G$ 3 dose limiting toxicities (DLTs) were noted, an additional
cohort of 3 pts was entered at the next dose level. Dose escalations
were to stop if $ 2 DLTs occurred at a M dose (MTD). Grade
(G) 4 OM, G4 diarrhea, $ G3 rash, & $ G3 cardiac toxicity were
considered as DLT; G 3/4 hematological toxicity was acceptable.
The G of OM was assessed daily (WHO OM scale-G 0-4).
Results:Nineteen pts were enrolled from 06/2007 to 06/2011. Data
on 15 evaluable pts is reported as 4 pts were removed. Median age
was 59 years (36-67).
Table.
Patient Characteristics (N 5 15)Sex – Male- no. (%) 8 (53)
Median Age- yr (Range) 59 (36-67)
Race- Caucasian- no. (%) 12 (80)
Median Creatinine clearance (Range) 42.8 (29-60)
Disease Status at the time of
Transplant– no. (%)CR 4 (27)
VGPR 3 (20)
PR 3 (20)
PD 5 (33)
Median no. of infused CD34+ cells x
10^6/Kg (Range)4.2 (2.6 - 8.0)Median number of days to neutrophil
engraftment (Range)12 (11-21)Median number of days to platelet
engraftment (Range)19 (0 - 86)Median duration of hospitalization-
days (Range)16 (12 -74)The overall incidence of OM$G3 was 53% (8/15) and a median
duration of$G3OMwas 6.5 days (3-42). One patient in L2 (M 160
mg/m2) developed atrial fibrillation. Two pts in L4 (M 200mg/m2)
developed G4 OM, hence reaching DLT. Three more pts were
then enrolled in L3 (M 180mg/m2). No DLT was observed in 6
pts enrolled in L3. Fourteen pts were evaluable for response at
D+100 (4 CRs). One patient died in L4 due to multi-organ failure
and infection. The most common adverse events include rash (13
events, no G 3), asymptomatic elevation of amylase (9, 3 pts G 3)
and lipase (2, 1 pt G 3) and diarrhea (12, 1 pt G 3 (C.Difficile +ve)).
Nine pts required narcotics; 4 pts neededTPN/NG feeding.Median
duration of hospitalization for ASCT was 16 days (12-74).
